# LAI Weekly Newsletter - Week of 2025-12-23

**Generated:** December 23, 2025 | **Items:** 5 signals | **Coverage:** 2 sections

## üéØ TL;DR
‚Ä¢ Teva Pharmaceuticals submitted a New Drug Application for an olanzapine long-acting injectable, a regulatory milestone for its partnership with MedinCell on LAI technologies.

‚Ä¢ Nanexa and Moderna entered into a license and option agreement for developing LAI formulations, signaling a major partnership in the LAI space.

‚Ä¢ MedinCell, a leader in LAI technologies, bolstered its financial position through a successful capital raise, supporting further development of its LAI pipeline.

## üì∞ Introduction
This week's LAI newsletter covers 5 key developments, including 2 regulatory updates and 3 new partnerships and deals in the long-acting injectable technology space. Executives can expect to gain insights into the latest regulatory landscape and strategic collaborations shaping the future of this innovative drug delivery approach.

---

## üìã Regulatory Updates
*2 items ‚Ä¢ Sorted by score*

### üìã Teva Pharmaceuticals, a partner of Medincell, has submitted a New Drug Application to the U.S. FDA f
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 12.2 ‚Ä¢ **Date:** Dec 23, 2025

Teva Pharmaceuticals, a partner of Medincell, has submitted a New Drug Application to the U.S. FDA for an olanzapine extended-release injectable suspension (TEV-'749 / mdc-TJK) for the once-monthly treatment of schizophrenia in adults.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf)


---

### üìã Teva is preparing to submit a New Drug Application (NDA) for an olanzapine long-acting injectable (L
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 12.2 ‚Ä¢ **Date:** Dec 23, 2025

Teva is preparing to submit a New Drug Application (NDA) for an olanzapine long-acting injectable (LAI) formulation to the US FDA in Q4 2025. Their product UZEDY¬Æ continues to show strong growth.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf)


---

## ü§ù Partnerships & Deals
*3 items ‚Ä¢ Sorted by date*

### ü§ù Nanexa and Moderna have entered into a license and option agreement for the development of up to fiv
**Source:** press_corporate__nanexa ‚Ä¢ **Score:** 11.8 ‚Ä¢ **Date:** Dec 23, 2025

Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell¬Æ technology. Nanexa will receive an upfront payment and is eligible for milestone payments and royalties.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/)


---

### ü§ù MedinCell, a company focused on long-acting injectable (LAI) technologies, has been awarded a new gr
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 11.5 ‚Ä¢ **Date:** Dec 23, 2025

MedinCell, a company focused on long-acting injectable (LAI) technologies, has been awarded a new grant to support its work in fighting malaria. This partnership highlights MedinCell's expertise in developing extended-release formulations for disease prevention and treatment.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf)


---

### üè¢ Medincell, a company specializing in long-acting injectable (LAI) technologies, will be added to the
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 6.2 ‚Ä¢ **Date:** Dec 23, 2025

Medincell, a company specializing in long-acting injectable (LAI) technologies, will be added to the MSCI World Small Cap Index, a leading global benchmark.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf)


---

## üìä Newsletter Metrics
- **Total Signals:** 5 items processed
- **Sources:** 2 unique sources
- **Key Players:** 
- **Technologies:** 
- **Generated:** 2025-12-23T10:44:30.788206Z